{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:19:58Z","timestamp":1773659998560,"version":"3.50.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1385\/ir:35:3:233","type":"journal-article","created":{"date-parts":[[2006,12,21]],"date-time":"2006-12-21T22:03:39Z","timestamp":1166738619000},"page":"233-248","source":"Crossref","is-referenced-by-count":20,"title":["Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease"],"prefix":"10.1007","volume":"35","author":[{"given":"Michael R.","family":"Batzloff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Olive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Good","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"3503233_CR1","volume-title":"Global Polio Eradication Initiative: Strategic Plan 2004\u20132008","author":"WHO","year":"2003","unstructured":"WHO: Global Polio Eradication Initiative: Strategic Plan 2004\u20132008. World Health Organization. Geneva, 2003."},{"key":"3503233_CR2","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1021\/ja00897a025","volume":"85","author":"RB Merrifield","year":"1963","unstructured":"Merrifield RB: Solid phase peptide synthesis I: The synthesis of a tetrapeptide. J Am Chem Soc 1963;85: 2149\u20132153.","journal-title":"J Am Chem Soc"},{"key":"3503233_CR3","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1021\/jo00795a005","volume":"37","author":"LA Carpino","year":"1972","unstructured":"Carpino LA, Han GY: The 9-fluorenylmethoxycarbonyl amino-protecting group. J Org Chem 1972;37:3404\u20133409.","journal-title":"J Org Chem"},{"key":"3503233_CR4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1399-3011.1990.tb00939.x","volume":"35","author":"GB Fields","year":"1990","unstructured":"Fields GB, Nobel RL: Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Intern J Pep Prot Res 1990;35:161\u2013214.","journal-title":"Intern J Pep Prot Res"},{"key":"3503233_CR5","unstructured":"Cherry DK, Woodwell DA: National Ambulatory Medical Care Survey: 2000 summary. Adv Data 2002;1\u201332."},{"key":"3503233_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJM200101183440308","volume":"344","author":"AL Bisno","year":"2001","unstructured":"Bisno AL: Acute pharyngitis. N Engl J Med 2001; 344:205\u2013211.","journal-title":"N Engl J Med"},{"key":"3503233_CR7","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1086\/444505","volume":"41","author":"AL Bisno","year":"2005","unstructured":"Bisno AL, Rubin FA, Cleary PP, Dale JB: Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles\u2014report of a National Institute of Allergy and Infectious Diseases Workshop. Clin Infect Dis 2005;41:1150\u20131156.","journal-title":"Clin Infect Dis"},{"key":"3503233_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02596317","volume":"1","author":"AL Komaroff","year":"1986","unstructured":"Komaroff AL, Pass TM, Aronson MD, et al: The prediction of streptococcal pharyngitis in adults. J Gen Intern Med 1986;1:1\u20137.","journal-title":"J Gen Intern Med"},{"key":"3503233_CR9","volume-title":"Rheumatic fever and streptococal infection","author":"BF Massell","year":"1997","unstructured":"Massell BF: Rheumatic fever and streptococal infection. Harvard University Press, Boston, 1997."},{"key":"3503233_CR10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1128\/CMR.13.3.470-511.2000","volume":"13","author":"MW Cunningham","year":"2000","unstructured":"Cunningham MW: Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000;13:470\u2013511.","journal-title":"Clin Microbiol Rev"},{"key":"3503233_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1440-1754.2002.00772.x","volume":"38","author":"AC Steer","year":"2002","unstructured":"Steer AC, Carapetis JR, Nolan TM, Shann F: Systematic review of rheumatic heart disease prevalence in children in developing countries: the role of environmental factors. J Paediatr Child Health 2002;38:229\u2013234.","journal-title":"J Paediatr Child Health"},{"key":"3503233_CR12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5694\/j.1326-5377.1996.tb122012.x","volume":"164","author":"JR Carapetis","year":"1996","unstructured":"Carapetis JR, Wolff DR, Currie BJ: Acute rheumatic fever and rheumatic heart disease in the top end of Australia's Northern Territory. Med J Aust 1996;164: 146\u2013149.","journal-title":"Med J Aust"},{"key":"3503233_CR13","first-page":"164","volume-title":"World Health Report. Office of Publications","author":"World Health Organization","year":"2000","unstructured":"World Health Organization World Health Report. Office of Publications, World Health Organization, Geneva, 2000, pp. 164\u2013169."},{"key":"3503233_CR14","first-page":"1","volume-title":"A review of WHO activities in, the burden of, and the evidence for strategies to control group A streptococcal diseases: part 3\u2014the current evidence for the burden of group A streptococcal diseases","author":"J Carapetis","year":"2004","unstructured":"Carapetis J: A review of WHO activities in, the burden of, and the evidence for strategies to control group A streptococcal diseases: part 3\u2014the current evidence for the burden of group A streptococcal diseases. University of Melbourne. Melbourne, 2004, pp. 1\u201349."},{"key":"3503233_CR15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","volume":"5","author":"JR Carapetis","year":"2005","unstructured":"Carapetis JR, Steer, AC, Mulholland EK, Weber M: The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5:685\u2013694.","journal-title":"Lancet Infect Dis"},{"key":"3503233_CR16","first-page":"244","volume":"4","author":"D Thomson","year":"1930","unstructured":"Thomson D, Thomson R: The role of the Streptococci in scarlet fever. Annals of the Pickett-Thomson Research Laboratory 1930;4:244\u2013252.","journal-title":"Annals of the Pickett-Thomson Research Laboratory"},{"key":"3503233_CR17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1084\/jem.150.4.862","volume":"150","author":"EH Beachey","year":"1979","unstructured":"Beachey EH, Stollerman GH, Johnson RH, Ofek I, Bisno AL. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. J Exp Med 1979;150: 862\u2013877.","journal-title":"J Exp Med"},{"key":"3503233_CR18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.124.6.1135","volume":"124","author":"EN Fox","year":"1966","unstructured":"Fox EN, Wittner MK, Dorfman A: Antigenicity of the M proteins of group A hemolytic streptococci. 3. Antibody responses and cutaneous hypersensitivity in humans. J Exp Med 1966;124:1135\u20131151.","journal-title":"J Exp Med"},{"key":"3503233_CR19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1128\/am.16.3.509-518.1968","volume":"16","author":"BF Massell","year":"1968","unstructured":"Massell BF, Michael JG, Amezcua J, Siner M: Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children. Appl Microbiol 1968;16:509\u2013518.","journal-title":"Appl Microbiol"},{"key":"3503233_CR20","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/infdis\/120.5.598","volume":"120","author":"EN Fox","year":"1969","unstructured":"Fox EN, Pachman LM, Wittner MK, Dorfman A: Primary immunization of infants and children with group A streptococcal M protein. J Infect Dis 1969;120: 598\u2013604.","journal-title":"J Infect Dis"},{"key":"3503233_CR21","first-page":"108","volume":"12","author":"IM Lyampert","year":"1966","unstructured":"Lyampert IM, Danilova TA, Borodyuk NA, Beletskaya LV: Mechanism of formation of antibodies to heart tissue in immunization with group A streptococci. Folia Biol (Praha) 1966;12:108\u2013115.","journal-title":"Folia Biol (Praha)"},{"key":"3503233_CR22","first-page":"212","volume":"85","author":"EH Beachey","year":"1972","unstructured":"Beachey EH, Stollerman GH: The common antigen(s) of streptococcal M protein vaccines causing hyperimmune reactions in man. Trans Assoc Am Physicians 1972; 85:212\u2013221.","journal-title":"Trans Assoc Am Physicians"},{"key":"3503233_CR23","first-page":"1115","volume":"207","author":"BF Massell","year":"1969","unstructured":"Massell BF, Honikman LH, Amezcua J: Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA 1969;207:1115\u20131119.","journal-title":"Report of three cases. JAMA"},{"key":"3503233_CR24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/br.38.1.57-86.1974","volume":"38","author":"EN Fox","year":"1974","unstructured":"Fox EN: M proteins of group A streptococci. Bacteriol Rev 1974;38:57\u201386.","journal-title":"Bacteriol Rev"},{"key":"3503233_CR25","doi-asserted-by":"publisher","first-page":"7878","DOI":"10.1128\/IAI.73.12.7878-7886.2005","volume":"73","author":"HS Park","year":"2005","unstructured":"Park HS, Cleary PP: Active and passive intranasal immunizations with streptococcal surface protein c5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun 2005;73:7878\u20137886.","journal-title":"Infect Immun"},{"key":"3503233_CR26","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/j.vaccine.2004.01.043","volume":"22","author":"DJ McMillan","year":"2004","unstructured":"McMillan DJ, Batzloff MR, Browning CL, et al Identification and assessment of new vaccine candidates for group A streptococcal infections. Vaccine 2004;22: 2783\u20132790.","journal-title":"Vaccine"},{"key":"3503233_CR27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/978-1-4899-1825-3_214","volume":"418","author":"JB Zabriskie","year":"1997","unstructured":"Zabriskie JB, Poon-King T, Blake MS, Michon F, Yoshinaga M: Phagocytic, serological, and protective properties of streptococcal group A carbohydrate antibodies. Adv Exp Med Biol 1997;418:917\u2013919.","journal-title":"Adv Exp Med Biol"},{"issue":"Suppl 2","key":"3503233_CR28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/10.Supplement_2.S356","volume":"10","author":"VA Fischetti","year":"1988","unstructured":"Fischetti VA, Jones KF, Hollingshead SK, Scott JR: Structure, function, and genetics of streptococcal M protein. Rev Infect Dis 1988;10(Suppl 2):S356\u2013359.","journal-title":"Rev Infect Dis"},{"key":"3503233_CR29","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1128\/IAI.70.4.2171-2177.2002","volume":"70","author":"MC Hu","year":"2002","unstructured":"Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB: Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002;70:2171\u20132177.","journal-title":"Infect Immun"},{"key":"3503233_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jama.292.6.709","volume":"292","author":"KL Kotloff","year":"2004","unstructured":"Kotloff KL, Corretti M, Palmer K, et al Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA 2004;292:709\u2013715.","journal-title":"JAMA"},{"key":"3503233_CR31","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1128\/iai.56.10.2666-2672.1988","volume":"56","author":"D Bessen","year":"1988","unstructured":"Bessen D, Fischetti VA: Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun 1988;56:2666\u20132672.","journal-title":"Infect Immun"},{"key":"3503233_CR32","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1128\/CDLI.12.7.833-836.2005","volume":"12","author":"JB Dale","year":"2005","unstructured":"Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B: Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immunol 2005;12:833\u2013836.","journal-title":"Clin Diagn Lab Immunol"},{"key":"3503233_CR33","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1086\/444458","volume":"41","author":"SA McNeil","year":"2005","unstructured":"McNeil SA, Halperin SA, Langley JM, et al: Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005;41:1114\u20131122.","journal-title":"Clin Infect Dis"},{"key":"3503233_CR34","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1084\/jem.167.6.1945","volume":"167","author":"D Bessen","year":"1988","unstructured":"Bessen D, Fischetti VA: Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J Exp Med 1988;167:1945\u20131950.","journal-title":"J Exp Med"},{"key":"3503233_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1078\/1438-4221-00241","volume":"293","author":"P Brandtzaeg","year":"2003","unstructured":"Brandtzaeg P: Role of secretory antibodies in the defence against infections. Int J Med Microbiol 2003;293:3\u201315.","journal-title":"Int J Med Microbiol"},{"key":"3503233_CR36","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4049\/jimmunol.148.3.888","volume":"148","author":"MS Bronze","year":"1992","unstructured":"Bronze MS, Courtney HS, Dale JB: Epitopes of group-a streptococcal M-protein that evoke cross-protective local immune-responses. J Immunol 1992;148:888\u2013893.","journal-title":"J Immunol"},{"key":"3503233_CR37","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0140-6736(94)92083-4","volume":"344","author":"S Pruksakorn","year":"1994","unstructured":"Pruksakorn S, Currie B, Brandt E, et al: Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci. Lancet 1994;344:639\u2013642.","journal-title":"Lancet"},{"key":"3503233_CR38","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.4049\/jimmunol.149.8.2729","volume":"149","author":"S Pruksakorn","year":"1992","unstructured":"Pruksakorn S, Galbraith A, Houghten RA, Good MF: Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. J Immunol 1992;149:2729\u20132735.","journal-title":"J Immunol"},{"key":"3503233_CR39","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/intimm\/9.11.1723","volume":"9","author":"WA Hayman","year":"1997","unstructured":"Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF: Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 1997;9:1723\u20131733.","journal-title":"Int Immunol"},{"key":"3503233_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1046\/j.1365-2567.1996.d01-754.x","volume":"89","author":"ER Brandt","year":"1996","unstructured":"Brandt ER, Hayman WA, Currie B, et al: Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology 1996;89:331\u2013337.","journal-title":"Immunology"},{"issue":"Suppl","key":"3503233_CR41","first-page":"104","volume":"119","author":"M Batzloff","year":"2004","unstructured":"Batzloff M, Yan H, Davies M, Hartas J, Good M: Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Indian J Med Res 2004;119(Suppl):104\u2013107.","journal-title":"Indian J Med Res"},{"key":"3503233_CR42","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1086\/374800","volume":"187","author":"MR Batzloff","year":"2003","unstructured":"Batzloff MR, Hayman WA, Davies MR, et al: Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003;187:1598\u20131608.","journal-title":"J Infect Dis"},{"key":"3503233_CR43","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1086\/466528","volume":"192","author":"MR Batzloff","year":"2005","unstructured":"Batzloff MR, Yan H, Davies MR, et al: Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. J Infect Dis 2005;192:1450\u20131455.","journal-title":"J Infect Dis"},{"key":"3503233_CR44","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/intimm\/11.4.569","volume":"11","author":"ER Brandt","year":"1999","unstructured":"Brandt ER, Hayman WA, Currie B, et al: Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. Int Immunol 1999;11:569\u2013576.","journal-title":"Int Immunol"},{"key":"3503233_CR45","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/infdis\/138.6.712","volume":"138","author":"R D'Alessandri","year":"1978","unstructured":"D'Alessandri R, Plotkin G, Kluge RM, et al Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis 1978;138:712\u2013718.","journal-title":"J Infect Dis"},{"key":"3503233_CR46","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1128\/IAI.68.12.6587-6594.2000","volume":"68","author":"ER Brandt","year":"2000","unstructured":"Brandt ER, Teh T, Relf WA, Hobb RI, Good MF: Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci. Infect Immun 2000;68:6587\u20136594.","journal-title":"Infect Immun"},{"key":"3503233_CR47","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1016\/S0264-410X(02)00205-0","volume":"20","author":"C Olive","year":"2002","unstructured":"Olive C, Clair T, Yarwood P, Good MF: Protection of mice from group A streptococcal infection by intranasal immunization with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 2002;20:2816\u20132825.","journal-title":"Vaccine"},{"key":"3503233_CR48","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/74719","volume":"6","author":"ER Bran5dt","year":"2000","unstructured":"Bran5dt ER, Sriprakash KS, Hobb RI, et al: New multideterminant strategy for a group A streptococcal vacciae designed for the Australian Aboriginal population. Nat Med 2000;6:455\u2013459.","journal-title":"Nat Med"},{"key":"3503233_CR49","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S0264-410X(97)00085-6","volume":"15","author":"DC Jackson","year":"1997","unstructured":"Jackson DC, O'Brien-Simpson N, Ede NJ, Brown LE: Free radical induced polymerization of synthetic peptides into polymeric immunogens. Vaccine 1997; 15:1697\u20131705.","journal-title":"Vaccine"},{"key":"3503233_CR50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1432-1033.1973.tb02757.x","volume":"34","author":"K Hantke","year":"1973","unstructured":"Hantke K, Braun V: Covalent binding of lipid to protein. Diglyceride and amide-linked fatty acid at the N-terminal end of the murein-lipoprotein of the Escherichia coli outer membrane. Eur J Biochem 1973;34:284\u2013296.","journal-title":"Eur J Biochem"},{"key":"3503233_CR51","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0264-410X(97)00219-3","volume":"15","author":"CJ Luke","year":"1997","unstructured":"Luke CJ, Huebner RC, Kasmiersky V, Barbour AG: Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi. Vaccine 1997;15:739\u2013746.","journal-title":"Vaccine"},{"key":"3503233_CR52","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1001\/jama.271.22.1764","volume":"271","author":"D Keller","year":"1994","unstructured":"Keller D, Koster FT, Marks DH, Hosbach P, Erdile LF, Mays JP: Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 1994; 271:1764\u20131768.","journal-title":"JAMA"},{"key":"3503233_CR53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.142.2.473","volume":"142","author":"F Melchers","year":"1975","unstructured":"Melchers F, Braun V, Galanos C: The lipoprotein of the outer membrane of Escherichia coli: a B-lymphocyte mitogen. Exp Med 1975;142:473\u2013482.","journal-title":"Exp Med"},{"key":"3503233_CR54","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1128\/iai.64.9.3845-3852.1996","volume":"64","author":"MV Norgard","year":"1996","unstructured":"Norgard MV, Arndt LL, Akins DR, Curetty LL, Harrich DA, Radolf JD: Activation of human monocytic cells by Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides proceeds via a path way distinct from that of lipopolysaccharide but involves the transcriptional activator NF-[kappa]B. Infect Immun 1996;64:3845\u20133852.","journal-title":"Infect Immun"},{"key":"3503233_CR55","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1365-2567.1997.00365.x","volume":"92","author":"M Kreutz","year":"1997","unstructured":"Kreutz M, Ackermann U, Hauschildt S, et al: A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and staphyloccocus aureus in human monocytes. Immunology 1997;92:396\u2013401.","journal-title":"Immunology"},{"key":"3503233_CR56","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1515\/bchm2.1983.364.1.593","volume":"364","author":"KH Wiesmuller","year":"1983","unstructured":"Wiesmuller KH, Bessler W, Jung G: Synthesis of the mitogenic S-[2,3-bis(palmitoyloxy)propyl]-N-palmitoylpentapeptide from Escherichia coli lipoprotein. Hoppe Seyler Physiol Chem 1983;364:593\u2013606.","journal-title":"Hoppe Seyler Physiol Chem"},{"key":"3503233_CR57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0171-2985(88)80036-6","volume":"177","author":"P Hoffmann","year":"1988","unstructured":"Hoffmann P, Heinle S, Schade UF, et al: Stimulation of human and murine adherent cells by bacterial lipoprotein and synthetic lipopeptide analogues. Immunobiology 1988;177:158\u2013170.","journal-title":"Immunobiology"},{"key":"3503233_CR58","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1042\/bj2670795","volume":"267","author":"R Seifert","year":"1990","unstructured":"Seifert R, Schultz G, Richter-Freund M, et al: Activation of superoxide formation and lysozyme release in human neutrophils by the synthetic lipopeptide Pam3Cys-Ser-(Lys)4. Involvement of guanine-nucleotide-binding proteins and synergism with chemotactic peptides. Biochem J 1990;267:795\u2013802.","journal-title":"Biochem J"},{"key":"3503233_CR59","doi-asserted-by":"crossref","first-page":"C1684","DOI":"10.1152\/ajpcell.1994.266.6.C1684","volume":"266","author":"M Berg","year":"1994","unstructured":"Berg M, Offermanns S, Seifert R, Schultz G: Synthetic lipopeptide Pam3CysSer(Lys)4 is an effective activator of human platelets. Am J Physiol 1994;266:C1684-C1691.","journal-title":"Am J Physiol"},{"key":"3503233_CR60","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0264-410X(89)90007-8","volume":"7","author":"K-H Wiesmuller","year":"1989","unstructured":"Wiesmuller K-H, Jung G, Hess G: Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator. Vaccine 1989;7:29\u201333.","journal-title":"Vaccine"},{"key":"3503233_CR61","doi-asserted-by":"publisher","first-page":"37692","DOI":"10.1074\/jbc.M105927200","volume":"276","author":"F Re","year":"2001","unstructured":"Re F, Strominger J-L: Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001;276:37692\u201337699.","journal-title":"J Biol Chem"},{"key":"3503233_CR62","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","volume":"21","author":"K Takeda","year":"2003","unstructured":"Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol 2003;21:335\u2013376.","journal-title":"Annu Rev Immunol"},{"key":"3503233_CR63","doi-asserted-by":"publisher","first-page":"15440","DOI":"10.1073\/pnas.0406740101","volume":"101","author":"DC Jackson","year":"2004","unstructured":"Jackson DC, Lau YF, Le T, et al: A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 2004; 101:15440\u201315445.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3503233_CR64","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.169.9.4905","volume":"169","author":"W Zeng","year":"2002","unstructured":"Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC: Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002;169:4905\u20134912.","journal-title":"J Immunol"},{"key":"3503233_CR65","doi-asserted-by":"publisher","first-page":"5409","DOI":"10.1073\/pnas.85.15.5409","volume":"85","author":"JP Tam","year":"1988","unstructured":"Tam JP Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988;85:5409\u20135413.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3503233_CR66","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/14760584.3.1.43","volume":"3","author":"C Olive","year":"2004","unstructured":"Olive C, Batzloff MR, Toth I: Lipid core peptide technology and group A streptococcal vaccine delivery. Expert Rev Vaccines 2004;3:43\u201358.","journal-title":"Expert Rev Vaccines"},{"key":"3503233_CR67","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/psc.467","volume":"9","author":"RP McGeary","year":"2003","unstructured":"McGeary RP, Olive C, Toth I: Lipid and carbohydrate based adjuvant\/carriers in immunology. J Pept Sci 2003;9:405\u2013418.","journal-title":"J Pept Sci"},{"key":"3503233_CR68","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2174\/1389557013406666","volume":"1","author":"C Olive","year":"2001","unstructured":"Olive C, Toth I, Jackson D: Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies. Mini Rev Med Chem 2001;1:429\u2013438.","journal-title":"Mini Rev Med Chem"},{"key":"3503233_CR69","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2174\/0929867013372535","volume":"8","author":"A Wong","year":"2001","unstructured":"Wong A, Toth I: Lipid, sugar and liposaccharide based delivery systems. Curr Med Chem 2001;8:1123\u20131136.","journal-title":"Curr Med Chem"},{"key":"3503233_CR70","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1046\/j.1440-1711.2002.01067.x","volume":"80","author":"WA Hayman","year":"2002","unstructured":"Hayman WA, Toth I, Flinn N, Scanlon M, Good MF: Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Immunol Cell Biol 2002;80:178\u2013187.","journal-title":"Immunol Cell Biol"},{"key":"3503233_CR71","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1128\/IAI.70.5.2734-2738.2002","volume":"70","author":"C Olive","year":"2002","unstructured":"Olive C, Batzloff MR, Horvath A, et al: A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun 2002;70: 2734\u20132738.","journal-title":"Infect Immun"},{"key":"3503233_CR72","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1128\/IAI.71.5.2373-2383.2003","volume":"71","author":"C Olive","year":"2003","unstructured":"Olive C, Batzloff M, Horvath A, et al: Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun 2003;71:2373\u20132383.","journal-title":"Infect Immun"},{"key":"3503233_CR73","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.vaccine.2005.01.041","volume":"23","author":"C Olive","year":"2005","unstructured":"Olive C, Hsien K, Horvath A, et al: Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Vaccine 2005;23:2298\u20132303.","journal-title":"Vaccine"},{"key":"3503233_CR74","first-page":"271","volume-title":"New Generation Vaccines","author":"G Lowell","year":"2004","unstructured":"Lowell G, Burt DS, White GL, Fries LF: Proteosome\u2122 technology for vaccines and adjuvants; in: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF (eds). New Generation Vaccines, 3rd ed. Marcel Dekker, New York, 2004; pp. 271\u2013282.","edition":"3rd ed"},{"key":"3503233_CR75","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.4049\/jimmunol.168.4.1533","volume":"168","author":"P Massari","year":"2002","unstructured":"Massari P, Henneke P, Ho Y, Latz E, Golenbock DT, Wetzler LM: Cutting edge: immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J Immunol 2002;168:1533\u20131537.","journal-title":"J Immunol"},{"key":"3503233_CR76","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1128\/IAI.72.6.3444-3450.2004","volume":"72","author":"P Mannam","year":"2004","unstructured":"Mannam P, Jones KF, Geller BL: Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun 2004;72:3444\u20133450.","journal-title":"Infect Immun"},{"key":"3503233_CR77","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1073\/pnas.071559398","volume":"98","author":"JJ Ferretti","year":"2001","unstructured":"Ferretti JJ, McShan WM, Ajdic D, et al Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc Natl Acad Sci USA 2001;98:4658\u20134663.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1385\/IR:35:3:233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1385\/IR:35:3:233\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1385\/IR:35:3:233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1385\/IR:35:3:233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:57:29Z","timestamp":1744149449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1385\/IR:35:3:233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["3503233"],"URL":"https:\/\/doi.org\/10.1385\/ir:35:3:233","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}